CR20210492A - ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS - Google Patents

ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS

Info

Publication number
CR20210492A
CR20210492A CR20210492A CR20210492A CR20210492A CR 20210492 A CR20210492 A CR 20210492A CR 20210492 A CR20210492 A CR 20210492A CR 20210492 A CR20210492 A CR 20210492A CR 20210492 A CR20210492 A CR 20210492A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antigen binding
binding fragments
amyloid
pyroglutamate
Prior art date
Application number
CR20210492A
Other languages
English (en)
Inventor
Marc Mercken
Sanjaya Singh
Porte Sherry La
Wilson Edwards
Jinquan Luo
Chichi Huang
Broeck Bianca Van
Rajkumar Ganesan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20210492A publication Critical patent/CR20210492A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona anticuerpos o fragmentos de unión al antígeno de estos que se unen a Aβ 3pE y métodos para elaborar y usar los anticuerpos o fragmentos de unión al antígeno de estos, que incluyen el uso para formulaciones, administración y kits. El anticuerpo y fragmentos de unión al antígeno de este y los métodos descritos son útiles para el diagnóstico, pronóstico y tratamiento de la enfermedad de Alzheimer u otras enfermedades relacionadas con el amiloide β.
CR20210492A 2019-03-26 2020-03-25 ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS CR20210492A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962823785P 2019-03-26 2019-03-26
PCT/EP2020/058395 WO2020193644A1 (en) 2019-03-26 2020-03-25 ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF

Publications (1)

Publication Number Publication Date
CR20210492A true CR20210492A (es) 2021-11-19

Family

ID=70008544

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210492A CR20210492A (es) 2019-03-26 2020-03-25 ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS

Country Status (21)

Country Link
US (3) US20220177560A1 (es)
EP (1) EP3946603A1 (es)
JP (1) JP2022526528A (es)
KR (1) KR20210143858A (es)
CN (1) CN113891746A (es)
AU (1) AU2020245031A1 (es)
BR (1) BR112021019107A2 (es)
CA (1) CA3134785A1 (es)
CL (2) CL2021002473A1 (es)
CO (1) CO2021014028A2 (es)
CR (1) CR20210492A (es)
DO (1) DOP2021000199A (es)
EA (1) EA202192606A1 (es)
EC (1) ECSP21079184A (es)
IL (1) IL286634A (es)
JO (1) JOP20210265A1 (es)
MA (1) MA55491A (es)
MX (1) MX2021011715A (es)
PE (1) PE20212266A1 (es)
SG (1) SG11202110504XA (es)
WO (1) WO2020193644A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
US11802149B2 (en) * 2021-10-28 2023-10-31 Abbvie Inc. Anti-amyloid beta antibodies and methods of using the same
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
WO2023170295A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
CN118459582A (zh) * 2024-07-11 2024-08-09 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
CN102131519B (zh) 2008-07-21 2016-01-13 前体生物药物股份公司 诊断抗体测定
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
AR080243A1 (es) * 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
BR112013004056B8 (pt) * 2010-08-12 2022-10-18 Lilly Co Eli Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
BR112018000097A2 (pt) * 2015-07-16 2018-09-04 Probiodrug Ag anticorpos humanizados
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
EP3249388A1 (en) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Method for diagnosing alzheimer´s disease
BR112018075300A2 (pt) 2016-06-07 2019-04-30 Biogen International Neuroscience Gmbh métodos para tratamento do mal de alzheimer
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
TWI669119B (zh) 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
PE20200695A1 (es) * 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
CN113164777A (zh) * 2018-09-27 2021-07-23 马伦戈治疗公司 Csf1r/ccr2多特异性抗体

Also Published As

Publication number Publication date
BR112021019107A2 (pt) 2021-11-30
PE20212266A1 (es) 2021-11-30
KR20210143858A (ko) 2021-11-29
CO2021014028A2 (es) 2021-10-29
DOP2021000199A (es) 2022-07-15
ECSP21079184A (es) 2021-11-30
CL2021002473A1 (es) 2022-04-22
US20220106387A1 (en) 2022-04-07
CA3134785A1 (en) 2020-10-01
AU2020245031A1 (en) 2021-10-21
JOP20210265A1 (ar) 2023-01-30
JP2022526528A (ja) 2022-05-25
MX2021011715A (es) 2021-12-10
EP3946603A1 (en) 2022-02-09
CL2022002670A1 (es) 2023-03-31
CN113891746A (zh) 2022-01-04
WO2020193644A1 (en) 2020-10-01
US11236155B2 (en) 2022-02-01
SG11202110504XA (en) 2021-10-28
EA202192606A1 (ru) 2022-01-24
US20200308261A1 (en) 2020-10-01
IL286634A (en) 2021-10-31
MA55491A (fr) 2022-02-09
US20220177560A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
CR20210492A (es) ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
PH12018502613A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
WO2019186276A8 (en) Antibody-based methods of detecting and treating alzheimer's disease
MX356800B (es) Anticuerpo tau humanizado.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
MA44917A1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
EA202100199A1 (ru) Моноклональные антитела, специфически связывающиеся с trbv-9 человека
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
WO2022082030A3 (en) Antigen-binding proteins and related methods of use
WO2021011673A3 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
ECSP19018367A (es) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6